In the past week, 1.1 million shares were added! Directors' large-scale increase in holdings sends a positive signal. Basestone Pharmaceutical-B (02616) opens up long-term growth space.

According to the Securities Times APP, it has been learned that leading innovative pharmaceutical company Foundation Medicine-B (02616) recently received strong support from multiple directors. Since June, Dr. Yang Jianxin, Executive Director and Chief Executive Officer (CEO), has increased his holdings in the company four times, buying a total of 650,000 shares; Chairman of the Board and Non-Executive Director Li Wei and Non-Executive Director Hitchner III Kenneth Walton also increased their holdings by 50,000 shares and 400,000 shares respectively. Several directors collectively increased their holdings by 1.1 million shares in the past week, with a total investment of approximately HK$4.95 million. This not only reflects a rational assessment of the company's asset value, but also a strong endorsement of the company's future development value.